BioChaperone Human Glucagon (recombinant human glucagon) / Adocia - LARVOL DELTA

Incorporating Caregiver Burden in Japans Cost-Effectiveness Evaluation: A Case Study of Teduglutide for Pediatric Short Bowel Syndrome (ISPOR 2025) - "This study aimed to integrate caregiver burden into cost-effectiveness evaluations within Japan’s healthcare system, using teduglutide, a recombinant human glucagon-like peptide 2 analogue that reduces PS dependence, as a case study. This study illustrates the practical steps for incorporating caregiver burden into Japan’s cost-effectiveness analyses, using pediatric SBS as an example. This expanded analysis captures a broader value, potentially guiding more informed resource allocation in Japan’s healthcare context."

Case study • Clinical • Cost effectiveness • HEOR • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Cost-Effectiveness of Teduglutide for Pediatric Patients with Short Bowel Syndrome in Japan, Including Caregiver Burden. (PubMed, Adv Ther) - "Incorporating the caregiver's burden in the cost-effectiveness analysis of teduglutide for pediatric patients with SBS provided a more comprehensive assessment of the value of teduglutide for patients, their families, and society. This approach enhances our understanding of the overall value of a treatment, especially for diseases with significant caregiver burden."

Cost effectiveness • HEOR • Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

THE EFFECT OF TEDUGLUTIDE ON THE UTILIZATION OF ENTERAL NUTRIENTS FOR THE SYNTHESIS OF HEPATIC, PANCREATIC AND MUCOSAL PROTEINS IN PATIENTS WITH SHORT BOWEL SYNDROME (DDW 2023) - "Teduglutide (TDG), a longer acting, recombinant human glucagon-like peptide-2 (GLP-2) analogue, has recently been shown to increase absorption by the residual bowel and thus reduce the need for HPN in patients with adapted SB-IF dependent on HPN. This increase in splanchnic amino acid turnover however, is not associated with albumin, trypsin, or mucosal protein synthesis. Supported by Shire Human Genetic Therapies, Inc., IIR-USA-001899 (O’Keefe)."

Clinical • Fibrosis • Gastrointestinal Disorder • Gene Therapies • Hepatology • Short Bowel Syndrome • Transplantation

Method for identification and quantification of intact teduglutide peptide using (RP)UHPLC-UV-(HESI/ORBITRAP)MS. (PubMed, Anal Methods) - "Teduglutide (Revestive®, 10 mg mL) is a recombinant human glucagon-like peptide 2 analogue, used in the treatment of short bowel syndrome, a serious and highly disabling condition which results from either too small a length of intestine or loss of critical intestinal function. To the best of our knowledge, the present work reports the first method developed for the simultaneous identification, structural characterization, and quantification of the therapeutic teduglutide peptide. Finally, the proposed method is able to indicate stability when quantifying the intact teduglutide since detects and characterises the exact mass of the degradation/modification products."

Journal • Gastrointestinal Disorder • Short Bowel Syndrome

Effectiveness of beinaglutide in a patient with late dumping syndrome after gastrectomy: A case report. (PubMed, Medicine (Baltimore)) - "These findings suggest that beinaglutide may be effective for treating post-gastrectomy late dumping syndrome."

Clinical • Journal • Gastric Cancer • Hypoglycemia • Oncology

Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia. (PubMed, Curr Diab Rep) - "Four main categories of glucagon formulation have been studied: intranasal glucagon, biochaperone glucagon, dasiglucagon, and non-aqueous soluble glucagon. As our experience with newer glucagon preparations increases, the role of glucagon is likely to expand beyond the emergency use that this medication has been limited to in the past. The innovations described in this review likely represent early examples of a pending large repertoire of indications for stable glucagon."

Journal • Review

Recombinant human glucagon-like peptide-1 protects against chronic intermittent hypoxia by improving myocardial energy metabolism and mitochondrial biogenesis. (PubMed, Mol Cell Endocrinol) - "rhGLP-1 protects against IH-induced cardiac injury by improving myocardial energy metabolism and enhancing the early adaptive changes of mitochondrial biogenesis."

Journal

PKC and PKA involved in the protection of rhGLP-1 on glomeruli and tubules in diabetic rats. (PubMed, J Diabetes Investig) - "These findings suggest that rhGLP-1 can reverse diabetic nephropathy by protecting both glomeruli and tubules by inhibiting PKC and activating PKA."

Journal • Preclinical

"$ADOC ia: BC Glucagon-Exenatide #ada19 poster - preclinical proof-of-concept in obesity https://t.co/nHuTNmPXUk" (@biotechradar_eu)

Preclinical

BioChaperone Glucagon Exenatide (BC Glu Exe), a Stable Combination of Glucagon (Glu) and Exenatide (Exe) Achieved Larger Body Weight (BW) Loss than Exe Alone in DIO Mice (ADA 2019) - "After 14 days, Exe and BC Glu Exe induced a BW loss of 10% and 25% respectively, compared to the vehicle. The BW loss was significantly more pronounced with BC Glu Exe than with Exe.In conclusion, these results support the testing of BC Glu Exe in clinics as a treatment for obesity."

Preclinical

"Adocia $ADOC BC Pram and BC Glucagon-GLP-1 planned trials have both shifted from Q1 to H1 and from H1 to H2 respectively" (@BiotechRadar)